A study conducted in adults and adolescents with myoclonic seizures (12 to 65 years) showed that 33.3% of the patients in the Keppra group and 30.0% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment.
Müoklooniliste krambihoogudega täiskasvanutel ja noortel (12… 65- aastased) läbi viidud uuring näitas, et 33, 3% Keppra- grupi ja 30, 0% platseebogrupi patsientidest kogesid raviga seotud kõrvaltoimeid.